Skip to main content
Erschienen in: Gastric Cancer 1/2019

01.01.2019 | Special Article

Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma

verfasst von: C. Mariette, F. Carneiro, H. I. Grabsch, R. S. van der Post, W. Allum, Giovanni de Manzoni, European Chapter of International Gastric Cancer Association

Erschienen in: Gastric Cancer | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Clinicopathological characteristics of gastric cancer (GC) are changing, especially in the West with a decreasing incidence of distal, intestinal-type tumours and the corresponding increasing proportion of tumours with Laurén diffuse or WHO poorly cohesive (PC) including signet ring cell (SRC) histology. To accurately assess the behaviour and the prognosis of these GC subtypes, the standardization of pathological definitions is needed.

Methods

A multidisciplinary expert team belonging to the European Chapter of International Gastric Cancer Association (IGCA) identified 11 topics on pathological classifications used for PC and SRC GC. The topics were debated during a dedicated Workshop held in Verona in March 2017. Then, through a Delphi method, consensus statements for each topic were elaborated.

Results

A consensus was reached on the need to classify gastric carcinoma according to the most recent edition of the WHO classification which is currently WHO 2010. Moreover, to standardize the definition of SRC carcinomas, the proposal that only WHO PC carcinomas with more than 90% poorly cohesive cells having signet ring cell morphology have to be classified as SRC carcinomas was made. All other PC non-SRC types have to be further subdivided into PC carcinomas with SRC component (< 90% but > 10% SRCs) and PC carcinomas not otherwise specified (< 10% SRCs).

Conclusion

The reported statements clarify some debated topics on pathological classifications used for PC and SRC GC. As such, this consensus classification would allow the generation of evidence on biological and prognostic differences between these GC subtypes.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.CrossRef
2.
Zurück zum Zitat Marrelli D, Pedrazzani C, Morgagni D, de Manzoni G, Pacelli F, Coniglio A, et al. Changing clinical and pathological features of gastric cancer over time. Bri J Surg. 2011;98:1273–83.CrossRef Marrelli D, Pedrazzani C, Morgagni D, de Manzoni G, Pacelli F, Coniglio A, et al. Changing clinical and pathological features of gastric cancer over time. Bri J Surg. 2011;98:1273–83.CrossRef
3.
Zurück zum Zitat Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18:1945–52.CrossRefPubMedPubMedCentral Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18:1945–52.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.PubMed Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.PubMed
5.
Zurück zum Zitat Laurén PA, Nevalainen TJ. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer. 1993;71:2926–33.CrossRefPubMed Laurén PA, Nevalainen TJ. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer. 1993;71:2926–33.CrossRefPubMed
6.
Zurück zum Zitat Lauwers GY, Carneiro F, Graham DY, Curado M-P, Franceschi S, Montgomery E, Tatematsu M, Hattori T: Gastric Carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system, 4th ed. IARC Press: Lyon; 2010, pp. 48–58. Lauwers GY, Carneiro F, Graham DY, Curado M-P, Franceschi S, Montgomery E, Tatematsu M, Hattori T: Gastric Carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system, 4th ed. IARC Press: Lyon; 2010, pp. 48–58.
7.
Zurück zum Zitat Piessen G, Messenger M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878–87.CrossRefPubMed Piessen G, Messenger M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878–87.CrossRefPubMed
9.
Zurück zum Zitat Bamboat ZM, Tang LH, Vinuela E, Kuk D, Gonen M, Shah MA, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol. 2014;21:1678–85.CrossRefPubMed Bamboat ZM, Tang LH, Vinuela E, Kuk D, Gonen M, Shah MA, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol. 2014;21:1678–85.CrossRefPubMed
10.
Zurück zum Zitat Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Different prognostic implications of gastric signet ring cell carcinoma: Stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 2017;265(5):946–53.CrossRefPubMedPubMedCentral Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Different prognostic implications of gastric signet ring cell carcinoma: Stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 2017;265(5):946–53.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Piessen G, Messager M, Robb WB, Bonnetain F, Mariette C. Gastric signet ring cell carcinoma: how to investigate its impact on survival. J Clin Oncol. 2013;31:2059–60.CrossRefPubMed Piessen G, Messager M, Robb WB, Bonnetain F, Mariette C. Gastric signet ring cell carcinoma: how to investigate its impact on survival. J Clin Oncol. 2013;31:2059–60.CrossRefPubMed
12.
Zurück zum Zitat Baiocchi GL, D’Ugo D, Coit D, Hardwick R, Kassab P, Nashimoto A, et al. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer. 2016;19:15–20.CrossRefPubMed Baiocchi GL, D’Ugo D, Coit D, Hardwick R, Kassab P, Nashimoto A, et al. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer. 2016;19:15–20.CrossRefPubMed
13.
Zurück zum Zitat De Manzoni G, Baiocchi GL, Framarini M, De Giuli M, D’Ugo D, Marchet A, et al. The SIC-GIRCG 2013 consensus conference on gastric cancer. Updates Surg. 2014;66:1–6.CrossRefPubMed De Manzoni G, Baiocchi GL, Framarini M, De Giuli M, D’Ugo D, Marchet A, et al. The SIC-GIRCG 2013 consensus conference on gastric cancer. Updates Surg. 2014;66:1–6.CrossRefPubMed
14.
Zurück zum Zitat Zamboni G, Franzin G, Scarpa A, Bonetti F, Pea M, Mariuzzi GM, et al. Carcinoma-like signet-ring cells in gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Am J Surg Pathol. 1996;20:588–98.CrossRefPubMed Zamboni G, Franzin G, Scarpa A, Bonetti F, Pea M, Mariuzzi GM, et al. Carcinoma-like signet-ring cells in gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Am J Surg Pathol. 1996;20:588–98.CrossRefPubMed
15.
Zurück zum Zitat Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H. Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Gastric Cancer. 2017;20:591–601.CrossRefPubMed Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H. Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Gastric Cancer. 2017;20:591–601.CrossRefPubMed
16.
Zurück zum Zitat Becker K, Mueller JD, Schumacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.CrossRefPubMed Becker K, Mueller JD, Schumacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.CrossRefPubMed
17.
Zurück zum Zitat Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathol Correlations Cancer. 1994;73:2680–6. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathol Correlations Cancer. 1994;73:2680–6.
18.
Zurück zum Zitat Philippron A, Bollschweiler E, Kunikata A, Plum P, Schmidt C, Favi F, et al. Prognostic relevance of lymph node regression after neoadjuvant chemoradiation for esophageal cancer. Semin Thorac Cardiovasc Surg. 2016;28:549–58.CrossRefPubMed Philippron A, Bollschweiler E, Kunikata A, Plum P, Schmidt C, Favi F, et al. Prognostic relevance of lymph node regression after neoadjuvant chemoradiation for esophageal cancer. Semin Thorac Cardiovasc Surg. 2016;28:549–58.CrossRefPubMed
19.
Zurück zum Zitat Hölscher AH, Drebber U, Schmidt H, Bollschweiler E. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma. Ann Surg. 2014;260:779–84.CrossRefPubMed Hölscher AH, Drebber U, Schmidt H, Bollschweiler E. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma. Ann Surg. 2014;260:779–84.CrossRefPubMed
20.
Zurück zum Zitat Bollschweiler E, Hölscher AH, Metzger R, Besch S, Mönig SP, Baldus SE, et al. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg. 2011;92:2020–7.CrossRefPubMed Bollschweiler E, Hölscher AH, Metzger R, Besch S, Mönig SP, Baldus SE, et al. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg. 2011;92:2020–7.CrossRefPubMed
21.
Zurück zum Zitat Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, et al. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol. 2010;17:3187–94.CrossRefPubMed Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, et al. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol. 2010;17:3187–94.CrossRefPubMed
22.
Zurück zum Zitat Shapiro J, Biermann K, van Klaveren D, Offerhaus GJ, Ten Kate FJ, Meijer SL, et al. Prognostic value of pretreatment pathological tumor extent in patients treated with neoadjuvant chemoradiotherapy plus surgery for esophageal or junctional cancer. Ann Surg. 2017;265:356–62.CrossRefPubMed Shapiro J, Biermann K, van Klaveren D, Offerhaus GJ, Ten Kate FJ, Meijer SL, et al. Prognostic value of pretreatment pathological tumor extent in patients treated with neoadjuvant chemoradiotherapy plus surgery for esophageal or junctional cancer. Ann Surg. 2017;265:356–62.CrossRefPubMed
23.
Zurück zum Zitat Nieman DR, Peyre CG, Watson TJ, Cao W, Lunt MD, Lada MJ, et al. Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy. Ann Thorac Surg. 2015;99:277–83.CrossRefPubMed Nieman DR, Peyre CG, Watson TJ, Cao W, Lunt MD, Lada MJ, et al. Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy. Ann Thorac Surg. 2015;99:277–83.CrossRefPubMed
24.
Zurück zum Zitat Zanoni A, Verlato G, Giacopuzzi S, Motton M, Casella F, Weindelmayer J, et al. ypN0: Does it matter how you get there? Nodal downstaging in esophageal cancer. Ann Surg Oncol. 2016;23(Suppl 5):998–1004.CrossRefPubMed Zanoni A, Verlato G, Giacopuzzi S, Motton M, Casella F, Weindelmayer J, et al. ypN0: Does it matter how you get there? Nodal downstaging in esophageal cancer. Ann Surg Oncol. 2016;23(Suppl 5):998–1004.CrossRefPubMed
25.
Zurück zum Zitat Mori M, Sakaguchi H, Akazawa K, Tsuneyoshi M, K Sueishi K, Sugimachi K. Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma. Hum Pathol. 1995;26:504–8.CrossRefPubMed Mori M, Sakaguchi H, Akazawa K, Tsuneyoshi M, K Sueishi K, Sugimachi K. Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma. Hum Pathol. 1995;26:504–8.CrossRefPubMed
26.
Zurück zum Zitat Min BH, Kim KM, Park CK, Lee JH, Rhee PL, Rhee JC, et al. Outcomes of endoscopic submucosal dissection for differentiated-type early gastric cancer with histological heterogeneity. Gastric Cancer. 2015;18:618–26.CrossRef Min BH, Kim KM, Park CK, Lee JH, Rhee PL, Rhee JC, et al. Outcomes of endoscopic submucosal dissection for differentiated-type early gastric cancer with histological heterogeneity. Gastric Cancer. 2015;18:618–26.CrossRef
27.
Zurück zum Zitat Miyamae M, Komatsu S, Ichikawa S, Kosuga T, Kubota T, Okamoto K, et al. Histological mixed-type as an independent risk factor for nodal metastasis in submucosal gastric cancer. Tumour Biol. 2016;37:709–14.CrossRefPubMed Miyamae M, Komatsu S, Ichikawa S, Kosuga T, Kubota T, Okamoto K, et al. Histological mixed-type as an independent risk factor for nodal metastasis in submucosal gastric cancer. Tumour Biol. 2016;37:709–14.CrossRefPubMed
28.
Zurück zum Zitat Carneiro, F. Classification of gastric carcinoma. Curr Diag Pathol. 2017;4:5. Carneiro, F. Classification of gastric carcinoma. Curr Diag Pathol. 2017;4:5.
29.
Zurück zum Zitat Stelzner S, Emmrich P. The mixed type in Laurén’s classification of gastric carcinoma. Histologic description and biologic behavior. Gen Diagn Pathol. 1997;143:39–48.PubMed Stelzner S, Emmrich P. The mixed type in Laurén’s classification of gastric carcinoma. Histologic description and biologic behavior. Gen Diagn Pathol. 1997;143:39–48.PubMed
30.
Zurück zum Zitat Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, et al. Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch. 2008;452:525–34.CrossRefPubMedPubMedCentral Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, et al. Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch. 2008;452:525–34.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Hanaoka N, Tanabe S, Mikami T, Okayasu I, Saigenji K. Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis: feasibility of endoscopic submucosal dissection. Endoscopy. 2009;41:427–32.CrossRef Hanaoka N, Tanabe S, Mikami T, Okayasu I, Saigenji K. Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis: feasibility of endoscopic submucosal dissection. Endoscopy. 2009;41:427–32.CrossRef
32.
Zurück zum Zitat Shimizu H, Ichikawa D, Komatsu S, Okamoto K, Shiozaki A, Fujiwara H, et al. The decision criterion of histological mixed type in “T1/T2” gastric carcinoma-comparison between TNM classification and Japanese Classification of Gastric Cancer. J Surg Oncol. 2012;105:800–4.CrossRefPubMed Shimizu H, Ichikawa D, Komatsu S, Okamoto K, Shiozaki A, Fujiwara H, et al. The decision criterion of histological mixed type in “T1/T2” gastric carcinoma-comparison between TNM classification and Japanese Classification of Gastric Cancer. J Surg Oncol. 2012;105:800–4.CrossRefPubMed
33.
Zurück zum Zitat Park HK, Lee KY, Yoo MW, Hwang TS, Han HS. Mixed carcinoma as an independent prognostic factor in submucosal invasive gastric carcinoma. J Korean Med Sci. 2016;31:866–72.CrossRefPubMedPubMedCentral Park HK, Lee KY, Yoo MW, Hwang TS, Han HS. Mixed carcinoma as an independent prognostic factor in submucosal invasive gastric carcinoma. J Korean Med Sci. 2016;31:866–72.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat van der Post RS, Gullo I, Oliveira C, Tang LH, Grabsch HI, O’Donovan M, et al. Histopathological, molecular, and genetic profile of hereditary diffuse gastric cancer. Current knowledge and challenges for the future. Adv Exp Med Biol. 2016;908:371–91.CrossRefPubMed van der Post RS, Gullo I, Oliveira C, Tang LH, Grabsch HI, O’Donovan M, et al. Histopathological, molecular, and genetic profile of hereditary diffuse gastric cancer. Current knowledge and challenges for the future. Adv Exp Med Biol. 2016;908:371–91.CrossRefPubMed
35.
Zurück zum Zitat Kwon CH, Kim YK, Lee S, Kim A, Park HJ, Choi Y, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology. 2018;72:556–68.CrossRefPubMed Kwon CH, Kim YK, Lee S, Kim A, Park HJ, Choi Y, et al. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology. 2018;72:556–68.CrossRefPubMed
36.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
37.
Zurück zum Zitat Fujimoto A, Ishikawa Y, Ishii T, Yamada A, Igarashi Y, Ohmoto Y, et al. Differences between gastric signet-ring cell carcinoma and poorly differentiated adenocarcinoma: a comparison of histopathologic features determined by mucin core protein and trefoil factor family peptide immunohistochemistry. Pathol Int. 2017;67:398–403.CrossRefPubMed Fujimoto A, Ishikawa Y, Ishii T, Yamada A, Igarashi Y, Ohmoto Y, et al. Differences between gastric signet-ring cell carcinoma and poorly differentiated adenocarcinoma: a comparison of histopathologic features determined by mucin core protein and trefoil factor family peptide immunohistochemistry. Pathol Int. 2017;67:398–403.CrossRefPubMed
Metadaten
Titel
Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma
verfasst von
C. Mariette
F. Carneiro
H. I. Grabsch
R. S. van der Post
W. Allum
Giovanni de Manzoni
European Chapter of International Gastric Cancer Association
Publikationsdatum
01.01.2019
Verlag
Springer Japan
Erschienen in
Gastric Cancer / Ausgabe 1/2019
Print ISSN: 1436-3291
Elektronische ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-018-0868-0

Weitere Artikel der Ausgabe 1/2019

Gastric Cancer 1/2019 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.